GILEAD SCIENCES, INC. is 31.7x more valuable than CRISPR Therapeutics AG by market capitalization ($151.05 B vs $4.77 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CRSP | GILD |
|---|---|---|
| Market cap | $4.77 B | $151.05 B |
| US-listed rank | #1422 | #99 |
| Revenue (latest FY) | $3.51M | $29.44B |
| Net income (latest FY) | -$581.60M | $8.51B |
| Net margin | -16569.8% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 837 | 981 |
GILEAD SCIENCES, INC. is 31.7x more valuable than CRISPR Therapeutics AG by market capitalization ($151.05 B vs $4.77 B).
In their latest fiscal years, CRISPR Therapeutics AG reported $3.51M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: CRISPR Therapeutics AG and GILEAD SCIENCES, INC., or browse the full rankings.